Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Brown

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Pediatric Pulmonology|September 13, 2022
Prevalence of chronic respiratory diseases in Aboriginal children: A whole population studyPamela Laird, Nicola Ball, Shekira Brahim, et al.
British Journal of Cancer|December 18, 2018
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Hazel Weir, Oona Delpuech, et al.
Cancer Research|August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical ModelsLenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Pediatric Pulmonology|September 13, 2022
Prevalence of chronic respiratory diseases in Aboriginal children: A whole population studyPamela Laird, Nicola Ball, Shekira Brahim, et al.
British Journal of Cancer|December 18, 2018
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Hazel Weir, Oona Delpuech, et al.
Cancer Research|August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical ModelsLenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.
Pageof 2